OBJECTIVE: While obstructive sleep apnea (OSA) is strongly related to obesity, few studies have examined polysomnographic (PSG) changes with major weight loss. We examined the effect of weight loss following laparoscopic adjustable gastric banding (LAGB) on the PSG changes in patients with severe OSA. In addition, we studied daytime sleepiness, the metabolic syndrome and quality of life (QOL). METHODS: A prospective study was conducted of 25 severely obese patients (17 men, eight women) with paired diagnostic PSG, biochemical and questionnaire studies, the first prior to LAGB and the second at least 1 y later. Subjects with a baseline apnea-hypopnea index (AHI) 425/h were included. RESULTS: Subject baseline age was 44.7 y, weight 154 kg and body mass index 52.7 kg/m 2 . The second PSG study was conducted 17.7710 (range 12-42) months after surgery and mean percentage of excess loss and weight loss were 50.1715% (range 24-80%) and 44.9722 kg (range 18-103 kg), respectively. There was a significant fall in AHI from 61.6734 to 13.4713, improved sleep architecture with increased REM and stage III and IV sleep, daytime sleepiness, as measured by Epworth Sleepiness Scale, of 1377.0 to 3.873.0, and fewer patients requiring nasal continuous positive airways pressure (CPAP). There were also major improvements in the metabolic syndrome, QOL, body image and fewer symptoms of depression (Po0.05 for all). CONCLUSION: Weight loss provides major improvement or resolution of OSA and CPAP requirements. It also reduces daytime sleepiness, and improves the metabolic syndrome and QOL. LAGB placement should be considered a broadly effective therapy for sleep apnea in the severely obese patient.
Introduction
Obesity, especially upper body obesity, is considered a major risk factor for obstructive sleep apnea (OSA). The estimates of prevalence of OSA in severely obese adults vary from 42-48% in men and 8-38% in women, a 10-fold increase in risk compared with that expected in adults. 1, 2 In addition to obesity, body shape and abnormal metabolic and inflammatory factors related to metabolic syndrome further increase the risk of OSA. 3 We have demonstrated that in addition to (BMI), hyperinsulinemia and impaired glucose metabolism are independent factors predicting significant OSA. 4 Severely obese patients with OSA have a high prevalence of the metabolic syndrome and are at significant risk of cardiovascular events. 3, 5 The current epidemic of obesity is likely to drive an increase in obesity-related sleep disorders, including OSA, just as it is driving epidemics of type 2 diabetes and the metabolic syndrome. [6] [7] [8] Obesity also has a major negative impact on both physical and mental components of health-related quality of life (QOL). 9, 10 Sleep disturbance in association with obesity may well contribute to this impairment. Several studies have now clearly demonstrated that, in the absence of OSA, obese patients commonly report symptoms of poor sleep quality and excessive daytime sleepiness, 4, [11] [12] [13] but the cause, in the absence of OSA, remains unclear. Patients with OSA also report impaired QOL compared with age-and sex-matched controls.
14 Current therapy for significant symptomatic OSA usually focuses on direct mechanical measures to reduce upper airway resistance and prevent obstruction. These therapies, including nasal continuous positive airways pressure (CPAP), mandibular advancement splints (MAS) and surgery to the upper airway, have variable compliance and efficacy. None of these options treat the accompanying comorbidity and physical and psychosocial disability in the severely obese patient.
Intentional weight loss appears to have major sleep benefits for obese subjects who achieve significant weight loss. These improvements are consistent for medical, dietary and surgical methods of weight loss. 11, [15] [16] [17] [18] Sleep disturbance understandably recurs with weight gain. We have previously reported a remarkable improvement in sleep symptoms and a reduction in daytime sleepiness with weight loss. 11 There have been a limited number of studies that have reported polysomnographic changes in sleep following bariatric surgery. These studies have generally been small and often only followed a small proportion of patients, but have all shown polysomnographic evidence of significant improvement or resolution of OSA (Table 1) . 17, [19] [20] [21] [22] None of these studies has simultaneously examined a broader range of outcomes, which could include an assessment of daytime sleepiness, biochemical markers of the metabolic syndrome, and psychological and QOL measures. We hypothesize that in severely obese patients with OSA, significant weight loss would provide effective therapy for OSA, daytime sleepiness, impaired QOL and cardiovascular risk associated with the metabolic syndrome. This study was designed to assess the effect of significant weight loss on apnea-hypopnea index (AHI), sleep parameters as measured by diagnostic polysomnography (PSG), symptoms of daytime sleepiness and a broad range of health and QOL outcome measures, in subjects who were found to have significant OSA prior to laparoscopic adjustable gastric band (LAGB) placement.
Methods
Patients with a BMI greater than 35 kg/m 2 , suffering from significant medical, physical or psychosocial disabilities and who have attempted weight reduction by other means for at least 5 y were considered for LAGB surgery. A description of the extensive preoperative assessment for these patients including consultations, anthropometric measurements, questionnaires and blood chemistry has been previously reported. 4 If a patient was considered at high risk or known to suffer from OSA during this period, a baseline diagnostic overnight PSG study was performed. Combination symptoms and clinical predictors of OSA in severely obese patients determined those at high risk. 4 If a patient was using CPCP therapy, a washout period of 1 week was advised prior to the diagnostic study. In the period between October 1, 1999 and the end of 2002, 49 subjects were found to have an AHI of greater than 25/h. After a period of at least 1 y following band placement, we asked these subjects to have a second diagnostic PSG and the preoperative anthropometric, questionnaire and biochemical data were again collected.
LAGB surgery LAGB surgery involves the placement of an adjustable silicone gastric band (Lap-Band System s , Inamed Health, Santa Barbara, CA, USA) just below the gastro-esophageal junction. The band has an inflatable inner balloon that can be adjusted by adding or removing normal saline via a small subcutaneous access port attached to the anterior rectus sheath. In this way, the band restriction can be altered to induce satiety in a controlled fashion. The weight loss, morbidity and mortality following LAGB surgery have recently been extensively reviewed. 23 
Questionnaires
Preoperatively and at annual follow-up visits, patients completed the Epworth Sleepiness Scale (ESS), a validated instrument that measures daytime sleepiness. 24 and the appearance orientation and evaluation sections of the multidimensional body self-relations questionnaire. 29 
Overnight polysomnography
Each patient had a full diagnostic PSG performed in a sleep laboratory, which included the following recordings: electroencephalography, chin and leg electromyography, electro-oculography, chest and abdominal inductance plethysmography, airflow (nasal) via a thermistor, oxygen saturation and heart-rate monitoring. A trained sleep technician staged each study using the Rechtschaffen and Weight loss and sleep apnea JB Dixon et al
Kales criteria 30 and scored each sleep study for arousals using the ASDA criteria. 31 Apneas were defined as complete cessation of airflow Z10 s. Hypopneas were defined as reduction of greater than 50% in one of three respiratory signalsFairflow signal, or respiratory or abdominal signals of respiratory inductance plethysmography, with an associated fall of Z2% in oxygen saturation. Preoperative excess weight is calculated as baseline weight (kg) less ideal weight (kg) as determined using the medium frame data from Metropolitan Life tables. 34 Percentage of excess weight loss is calculated by dividing the weight change between paired PSG studies by the excess weight preoperatively, multiplied by 100. 
Biochemistry-metabolic syndrome

Data analysis
Informed consent
All patients gave preoperative written informed consent to the procedure and follow-up requirements. The study was carried out in accordance with the Declaration of Helsinki.
Results
There were 49 subjects with an AHI of greater than 25 events per hour preoperatively who fulfilled the criteria for a second sleep study. A total of 27 agreed to have a second PSG study.
Of the remaining 22, 17 were contacted and refused a study, three were currently out of Australia, one was lost to followup and one was considered unfit for the washout period and diagnostic sleep study as she required BIPAP therapy. Two who agreed to a second diagnostic study still had not yet had it performed at the time of writing. Thus, we have 25 patients with paired studies. One of the 49 patients had had the band removed due to erosion of the band into the stomach. He refused a follow-up study. The major reasons for refusal (n ¼ 17) included no symptoms suggesting an ongoing problem, inconvenience, work commitments, while some found the previous study uncomfortable and unacceptable. The subjects who agreed to have a second study tended to have a higher baseline AHI, had a significantly higher ESS and were more likely to be using CPAP therapy prior to surgery ( Table 2 ). The second sleep study was performed at 17.7710 (range 12-42) months after surgery. At the time of the study, the subjects had lost a mean of 44.9722 kg (range 18-103 kg) in weight and had lost a mean 50.1715% (range 24-80%) of excess weight. Repeat testing showed that there was a significant fall in AHI and arousal index, and a significant increase in percentage of REM sleep and stage 3 and 4 sleep ( Table 3) . Only four of the 25 (16%) subjects had an AHI 425/h at the second study and each continued to use nasal CPAP therapy but required lower pressures in each case. Daytime sleepiness, as measured by the ESS, was also 4 There was no statistically significant correlation between the improvement in AHI and the percentage of excess weight loss, change in neck circumference or change in fasting insulin concentrations; however, the numbers in the study would not provide sufficient power to detect correlation coefficients less than 0.45. The Spearman's correlation coefficient for the change in AHI and change in neck circumference was 0.41, P ¼ 0.07. There were improvements in the key biochemical markers of the metabolic syndrome: lower fasting plasma glucose, insulin and triglycerides, and a significant rise in HDLcholesterol concentration. The QUICKI indirect measure of insulin sensitivity also improved (Table 3) . At baseline, 20 (80%) subjects fulfilled the criteria of the metabolic syndrome. At the time of the second PSG study, only three (12%) fulfilled these criteria. Preoperatively, four subjects had type 2 diabetes, three of whom were using oral hypoglycemic medication, and two subjects had impaired fasting glucose. At follow-up, one previously diabetic subject had impaired fasting glucose while the others had normal fasting glucose concentrations. None of the patients were using insulin or hypoglycemic medications.
The 25 studied patients also had major improvements in health-related QOL as measured by the SF-36, with significant improvement in all eight domain scores and follow-up scores similar to community normal values (Figure 1 ). There were also major improvements in body image with an improved appearance evaluation score and a reduction in symptoms of depression indicated by normal mean Beck 
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Depression Inventory scores at follow-up. Mean appearance evaluation scores were 1.8070.40 at baseline and 2.7670.76 at follow-up (Po0.001), and mean Beck Depression Inventory scores were 15.9710.8 at baseline and 6.278.3 (P ¼ 0.004) at follow-up.
The 21 patients not lost to follow-up or known to be out of Australia and who did not have repeat PSG study showed similar changes in other measures to the test group. The percentage of excess weight lost was 39, 49 and 51% of excess weight loss at 1, 2 and 3 y post band placement, respectively. The mean ESS score was in the normal range at 3.572.7 at their last annual review. None reported subjective sleepiness (ESS 410) at follow-up. A total of 14 patients were using nasal CPAP preoperatively and four continued to use it at the last annual follow-up visit. Five still fulfilled the criteria for the metabolic syndrome. This group also had similar and significant improvements in all SF-36 domain scores, Beck Depression Inventory and appearance evaluation scores (not shown). At the time of the second diagnostic sleep study (for those with paired studies) or the most recent annual review (for those who refused a repeat study), mean questionnaire scores for both groups were consistent with healthy community normal values for the following: all SF-36 domain scores, ESS and Beck Depression Inventory. At follow-up, we could not demonstrate any differences in weight loss, questionnaire responses and features of the metabolic syndrome between those who agreed to have a second study and those who did not.
Discussion
In this study, we have shown that significant weight loss has major benefits for severely obese subjects with OSA. Weight loss provides improvements in respiratory events during sleep, sleep quality, subjective sleepiness, biochemical measures of the metabolic syndrome, symptoms of depression and body image. These changes underlie the remarkable improvement in QOL. One may argue that only significant weight loss is likely to produce such widespread benefits in diseases and conditions so closely related to obesity. Changes in PSG at follow-up are consistent with those described following more invasive bariatric surgery such as vertical banded gastroplasty, Roux-en-Y gastric bypass and biliopancreatic diversion. [19] [20] [21] However, in the past, daytime sleepiness, metabolic health and health-related QOL have not been measured simultaneously. This study demonstrates improvement in sleep architecture in addition to a reduction in AHI, in association with weight loss. There is a significant increase in the percentage of REM sleep and in the percentage of deeper stages (III and IV) of sleep. These changes in sleep architecture are very similar to those described by Charuzi et al, 22 who studied 47 patients following vertical banded gastroplasty or gastric bypass.
A weakness of this and other studies of patients following bariatric surgery is the relatively low proportion of patients who agree to a repeat PSG following significant weight loss. In this study, we achieved just over 50% agreeing to a repeat study. It is interesting that the subjects who chose to have a repeat study were likely to have been more troubled by sleep disturbance prior to LAGB surgery. The reasons given for refusing a repeat PSG were also very similar to other studies. The majority of patients were asymptomatic, were not using CPAP therapy and saw no reason for the inconvenience of a repeat study. This reasoning is supported by questionnaire results and it is reassuring that weight loss, questionnaire and biochemical outcomes were comparable in those who did and did not have a second PSG. Ultimately, it is the improvement in health and QOL that our patients seek.
Currently, CPAP therapy is primary and standard therapy for symptomatic OSA. However, long-term compliance with CPAP therapy is a significant problem even in subjects with severe OSA with compliance rates of 50-80%. 36 If patients find it difficult to tolerate nasal CPAP therapy, alternative treatment options are limited. MAS provide an alternative, but are expensive and it is difficult to predict the 70% of patients who will have a partial improvement in their OSA. 37 Various surgical procedures specifically designed to reduce upper airways resistance have been devised, but none have a high level of evidence of efficacy. 38 Unfortunately, none of these therapies are likely to have significant effects on non-OSA-related obesity comorbidity. It is notable that the many patients in our study had poor QOL and daytime sleepiness despite nasal CPAP therapy. These problems may well be related to their obese state rather than OSA4. 39, 40 Given the very impressive and consistent data following bariatric surgery, we must consider why this therapy has not become a more generally used or commonly recommended therapy for the severely obese patient with significant, symptomatic OSA. The Cochrane review addressing surgical therapy for the treatment of sleep apnea did not address the issue of bariatric surgery, as the focus was on upper airway surgery. The review found no suitable studies and concluded that there was a need for high-quality randomized controlled trials (RCTs) in the field of surgery for OSA. 38 If the review had included the limited number of bariatric surgery publications, a similar conclusion would have been reached, as all studies to date are observational and therefore none provide high-level evidence. The dilemma regarding surgical therapy and RCTs is considerable, with many of the currently used surgical procedures accepted as standard or best care without having been subjected to the rigors of RCTs. There is room for argument regarding the appropriateness of RCTs for surgical therapy, and it has been proposed that consideration should be given to observational data that have a logical basis and provide clear evidence of substantial treatment effect, as these data are unlikely to systematically overestimate the magnitude of treatment effect. 41, 42 However, we accept current evidence-based principles, which would demand a Weight loss and sleep apnea JB Dixon et al higher level of evidence before this therapy should be broadly recommended and therefore note a pressing need for an RCT of bariatric surgery compared with currently accepted therapy for the treatment of OSA in severely obese patients. LAGB surgery provides a reliable, safe, minimally invasive approach to bariatric surgery. 23, 43 The band acts by inducing early satiation and prolonged satiety following a meal allowing for reduced caloric intake. 44 The tightness of the band can be adjusted by percutaneous injection of saline into a subcutaneous access port. This permits optimal induction of satiety without undue obstruction, generating a controlled rate of weight loss. The procedure has more recently become standardized, broadly acceptable and applicable, with many centers providing the procedure with less than 24 h length of stay. We now demonstrate the effectiveness in patients with severe obesity. LAGB surgery is therefore an appropriate candidate surgical procedure for further evaluation in the long-term management of symptomatic OSA in severely obese patients.
In conclusion, weight loss following LAGB surgery provides major improvement in a broad range of obesity-related comorbidities including OSA and daytime sleepiness. This surgery appears to provide a more logical definitive therapy for the patient with the combined, but related, problems of severe obesity and OSA. Meanwhile, there is a need to better evaluate the role and cost effectiveness of bariatric surgery using an RCT format. Our data would suggest that current standard therapy for OSA may not be the best-available care for these patients.
